A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Condition: Atopic Dermatitis Interventions: Drug: 1.5% QLM3003; Drug: 2% QLM3003; Drug: Vehicle (Placebo) Sponsor: Qilu Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials